Q4'FY25 Earnings Call Supplemental Presentation August 13, 2025 Safe Harbor Statement Statements in this presentation (including the oral commentary that accompanies it) that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation relate, but are not limited, to: expectations regarding adjusted EBITDA and revenue; our ability to execute on our ...

Core Insights - Accuray Incorporated presented over 40 clinical studies at the ESTRO 2025 meeting, highlighting the effectiveness of its CyberKnife® System in treating prostate cancer at various stages [1][2] - The studies emphasize the system's precision and ability to treat high-risk and recurrent prostate cancer, promoting a non-invasive treatment option [1][2] - Accuray's symposium at the meeting attracted 350 healthcare professionals, focusing on advancements in genitourinary radiotherapy [3] Clinical Data and Outcomes - A retrospective analysis involving 262 men over 70 or with severe comorbidities showed favorable outcomes with CyberKnife SBRT, reporting low rates of acute and late urogenital and gastrointestinal toxicities [4] - An early trial on stereotactic salvage radiotherapy (SSRT) for prostate bed recurrence after prostatectomy indicated mild toxicity and a shorter treatment duration compared to standard approaches [5] Company Commitment and Innovation - Accuray is dedicated to advancing radiation therapy solutions, aiming to improve patient care and outcomes through continuous innovation [6]

Company Overview - Accuray Incorporated has introduced the CyberKnife® System at the CyberKnife Center Salzburg, marking the first use of this technology in Austria, which enhances access to stereotactic radiosurgery (SRS) and ultra-hypofractionated stereotactic body radiation therapy (SBRT) [1][4] - The CyberKnife S7™ System allows for ultra-hypofractionated radiation therapy, delivering high doses of targeted radiation in just one to five outpatient sessions, significantly reducing the treatment time compared to conventional methods that often require 30-40 sessions [2][3] Clinical Impact - Evidence suggests that ultra-hypofractionation provides clinical outcomes comparable to conventional fractionation while reducing the number of treatments and overall care costs, leading to increased adoption of such treatments as standard care [3] - The CyberKnife System is viewed as a significant advancement in cancer care, enabling patients to receive precise and effective treatment in a shorter timeframe, which positively impacts their quality of life [5] Market Context - Cancer cases in Austria are projected to increase by nearly 25% from 2022 to 2040, highlighting the growing need for advanced cancer treatment options [4] - Despite Austria's strong reimbursement for oncology medications, the availability of radiotherapy equipment is 27% lower than the EU average, indicating a need for continued investment in technologies like the CyberKnife System to address this gap [4]